Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.

Dermatology (Basel, Switzerland) - 1 Jan 2016

Galluzzo Marco, Boca Andreea Nicoleta, Botti Elisabetta, Potenza Concetta, Malara Giovanna, Malagoli Piergiorgio, Vesa Stefan, Chimenti Sergio, Buzoianu Anca Dana, Talamonti Marina, Costanzo Antonio

Abstract excerpt

BACKGROUND: Psoriasis is characterized by multiple genetic variations. Some of these variations, such as the presence of HLA-Cw6 or TNFAIP3 single-nucleotide polymorphisms (SNPs), have been correlated to the response to biologic treatments. OBJECTIVE: The aim of our study was to evaluate the effects of IL12B and IL6 SNPs on the response to ustekinumab. METHODS: We retrospectively analyzed the genotypes of 64...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dermatologic Agents
Share to HLA-C Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-12 Subunit p40

Share to Interleukin-6

Share to Psoriasis

Share to Receptors, Interleukin

Share to Severity of Illness Index

Share to Treatment Outcome

Source

Identifiers

PMID: 26678060
DOI: 10.1159/000441719

Genes

TNFAIP3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.PMID 26678060Read ↗

Pharmacogenetics Update on Biologic Therapy in PsoriasisSemantic proximity Read ↗

Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.Semantic proximity Read ↗

Pharmacogenetics of psoriasis:<i>HLA-Cw6</i>but not<i>LCE3B/3C</i>deletion nor<i>TNFAIP3</i>polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumabSemantic proximity Read ↗

Genetic variations in IL6 and IL12B decreasing the risk for psoriasis.Semantic proximity Read ↗

Association between several immune response-related genes and the effectiveness of biological treatments in patients with moderate-to-severe psoriasis.Semantic proximity Read ↗

A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-α and Anti-IL-12/23 Agents.Semantic proximity Read ↗

Association of IL12B risk haplotype and lack of interaction with HLA-Cw6 among the psoriasis patients in India.Semantic proximity Read ↗

IL12B, IL23A, IL23R and HLA-C*06 genetic variants in psoriasis susceptibility and response to treatment.Semantic proximity Read ↗

Resequencing of the IL12B gene in psoriasis patients with the rs6887695/rs3212227 risk genotypes.Semantic proximity Read ↗

IL12B rs3213094 as a Predictor of Early Response to Biologic Therapy in Psoriasis: A Real-World Study in a Romanian Cohort.Semantic proximity Read ↗

Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis.Semantic proximity Read ↗

HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.